This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Dec 2011

Emergent Announces Plans for TRU-016 Program

Emergent announced the initiation of patient dosing in the Phase 2 study of TRU-016 in combination with bendamustine for patients with relapsed CLL.

Rockville-based biopharmaceutical company Emergent BioSolutions Inc. yesterday announced plans for its TRU-016 program following receipt of a notice from Abbott that it is terminating its co-development and co-commercialization agreement.


TRU-016, Emergent's humanized anti-CD37 mono-specific protein therapeutic, recently commenced a Phase 2 clinical study for chronic lymphocytic leukemia (CLL) and is currently in the middle of Phase 1b clinical evaluation in non-Hodgkin's lymphoma (NHL). These studies will be completed, and final study data will be available by 1H 2013.


Following the termination of the agreement, Emergent will retain worldwide rights for the development and commercialization of TRU-016, and Abbott will be obligated to provide certain forms of tra

Related News